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Abstract
We analysed trends in antimicrobial non-susceptibility in methi-
cillin-resistant Staphylococcus aureus (MSRA) from Germany to
assess the impact of the changing population structure of MRSA on
antimicrobial resistance rates. During two large nationwide
multicentre studies in 2004–2005 and 2010–2011, we collected
consecutively spa-genotyped MRSA isolates. The increase in
non-susceptibility rates for tetracycline and trimethoprim–sulpha-
methoxazole was associated with the spread of livestock-associ-
ated MRSA. A decrease in non-susceptibility rates for
aminoglycosides and quinolones affected all major lineages
(spa-clonal complexes 003, 008, and 032). All isolated remained
susceptible to glycopeptides and linezolid.
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Methicillin-resistant Staphylococcus aureus (MRSA) infections
are a challenge for healthcare systems around the globe. The
advent of novel clonal lineages belonging to community-asso-
ciated MRSA and livestock-associated (LA)-MRSA may have
jeopardized much of the success of the past years in combating
healthcare-related MRSA [1,2].
Many antimicrobial agents have been developed with either
bacteriostatic or bactericidal activity, but reduced susceptibil-
ity against anti-MRSA compounds is emerging [3]. For instance,
the increase in vancomycin MICs within the susceptibility range
(≤2 mg/L, vancomycin creep) is worrying, as it could be
associated with poorer outcome of infections [3,4]. Thus,
knowledge of the prevalence and trends of resistance of
circulating MRSA strains is needed to support the best possible
use of the remaining antibiotic armamentarium in empirical
chemotherapy.
The aim of this study was to systematically assess trends in
rates of resistance to antimicrobial agents in MRSA isolates
from Germany that have been genotypically characterized in a
previous survey [5]. Brieﬂy, 36 laboratories from different
regions in Germany were invited to participate in this survey,
and 33 laboratories contributed up to 50 consecutively
collected MRSA isolates during two studies (1 February 2004
to 31 January 2005, and 1 February 2010 to 31 January 2011).
Only one isolate per patient was included, and no exclusion
criteria were applied. Isolates were stored between20°C and
80°C in the participating laboratory, and were sent in a batch
after each sampling period to the Institute of Medical Micro-
biology, University Hospital M€unster, Germany. There, isolates
were stored at 80°C in bacterial storage systems (Cryobank;
Mast Diagnostica, Bootle, UK) and were subjected to suscep-
tibility testing after the sampling period of each study with the
Vitek 2 automated system (bioMerieux, Marcy l’Etoile, France)
and the antimicrobial susceptibility cards AST P549 (in 2004–
2005) and AST P580 (in 2010–2011). Both susceptibility test
cards (bioMerieux) include the same range of concentrations
for the same antibiotics, with the exception of an additional
dilution step for vancomycin (0.5 mg/L) in AST P580. No
changes were made during the two studies (hardware or
software) that would affect the measurement of MICs. The
MICs of the tested antimicrobial agents were interpreted
according to EUCAST clinical breakpoints (Version 3.1, 11
February 2013). As the lowest MIC of the antimicrobial
susceptibility cards for rifampicin is above the EUCAST
breakpoint for susceptibility, we used the CLSI breakpoints to
differentiate between intermediate and susceptible isolates [6].
All isolates were genotyped by the use of S. aureus
protein A typing (spa typing) [7]. Related spa types were
clustered into spa clonal complexes (spa-CCs) with the BURP
algorithm as implemented in the software Ridom StaphType
(2.2.1), with preset parameters as previously published [8].
The 50th and 90th percentiles of MIC (MIC50 and MIC90)
and MIC ranges were calculated with R software, ver-
sion 2.13.1 (http://cran.r-project.org) and the package ‘epicalc’.
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Non-susceptibility rates, which include both resistant and
intermediate categories, were compared by use of the chi-
squared test.
In total, 3207 MRSA isolates were included, and 3205 were
tested (2004–2005, n = 1603; 2010–2011, n = 1602). We
failed to reculture one isolate of each sampling period for
susceptibility testing after cryo-conservation.
We detected a signiﬁcant decrease in non-susceptibility
from 2004–2005 to 2010–2011 for gentamicin (OR 0.33,
95% CI 0.3–0.4, p <0.005) and tobramycin (OR 0.4,
95% CI 0.4–0.5, p <0.005; Table 1). This decrease in amino-
glycoside non-susceptibility was not restricted to a single
spa-CC but occurred in several lineages, including spa-CC 003
(associated with multilocus sequence typing sequence type
(ST)5, ST225, ‘Rhine-Hesse’ clone), spa-CC 032 (associated
with ST22, ‘Barnim’ clone), and spa-CC 008 (associated with
ST8, ST247, ST250, and ST254), but not in spa-CC 004 (ST45;
Table S1). All other rates of non-susceptibility of the tested
antibiotics remained unchanged in isolates belonging to the
three major spa types (t003, t008, and t032). This may suggest
that general changes in antimicrobial susceptibility are
explained by a general change in the MRSA population
structure (e.g. spread of the ‘Rhine-Hesse’ and ‘Barnim’
clones) rather than by the acquisition or loss of resistance
genes. However, the decrease in aminoglycoside non-suscep-
tibility might also be associated with the reduction in
aminoglycoside use from approximately 9 (2001) to 4 (2009)
deﬁned daily doses per 100 bed-days in Germany [9].
The overall non-susceptibility rates of levoﬂoxacin and
moxiﬂoxacin also decreased (OR 0.4, 95% CI 0.3–0.5,
p <0.005 each; Table 1), despite a continuous increase in
general quinolone use from approximately 15 (2001) to 18
(2009) deﬁned daily doses per 100 bed-days [9].
Non-susceptibility rates signiﬁcantly increased for tetracy-
cline, from 5.0% to 9.0% (OR 1.9, 95% CI 1.4–2.5, p <0.005).
Tetracycline non-susceptibility is highly prevalent among
LA-MRSA isolates, and stands in strong contrast to the trend
of decreasing tetracycline/doxycycline non-susceptibility that
has been observed in Germany in the past 30 years [10–12].
LA-MRSA isolates mainly belong to spa-CC 011, which is
indicative of ST398. Stratiﬁcation of resistance data in spa-CCs
showed high non-susceptibility rates for tetracycline (51.2%)
and trimethoprim–sulphamethoxazole (23.3%) and low
non-susceptibility rates for aminoglycosides (gentamicin,
4.7%; tobramycin, 17.4%) and quinolones (levoﬂoxacin and
moxiﬂoxacin, 46.5%) in isolates belonging to spa-CC 011 as
compared with other major lineages (including spa-CCs 003,
004, 008, and 032; Table S1). When all spa-CC 011 isolates
were excluded from the analysis, resistance rates in 2004–
2005 vs. 2010–2011 were apparently stable for tetracycline
(4.7% vs. 6.6%), trimethoprim–sulphamethoxazole (1.3 vs. 2.2),
and quinolones (96.2 vs. 92.0), and were reduced for
gentamicin (12.4 vs. 4.5) and tobramycin (64.4 vs. 43.4). This
ﬁnding shows that the recent increase in the proportion of
LA-MRSA in Germany from 0.2% (2004–2005) to 5.4% (2010–
2011) explains the increase in tetracycline and trimethoprim–
sulphamethoxazole non-susceptibility but not the decrease in
aminoglycoside non-susceptibility in the German MRSA
population [5]. The antimicrobial non-susceptibility rates in
LA-MRSA mirrors the proportion of antimicrobial consump-
tion in livestock in Germany (tetracycline, 54.3%; b-lactams,
23.0%, sulphonamides  trimethoprim, 12.7%) [13].
TABLE 1. Comparison of antibiotic MICs and non-susceptibility rates of MRSA isolates in Germany in 2004–2005 and 2010–2011




















Gentamicin ≤0.5 ≥16 ≤0.5/≥16 12.4 ≤0.5 ≤0.5 ≤0.5/≥16 4.5 <0.005
Tobramycin ≥16 ≥16 ≤1/≥16 64.3 ≤1 ≥16 ≤1/≥16 42.0 <0.005
Levoﬂoxacin ≥8 ≥8 ≤0.12/≥8 95.5 ≥8 ≥8 ≤0.12/≥8 89.6 <0.005
Moxiﬂoxacin 4 4 ≤0.25/≥8 96.0 4 4 ≤0.25/≥8 89.6 <0.005
Erythromycin ≥8 ≥8 ≤0.25/≥8 79.0 ≥8 ≥8 ≤0.25/≥8 74.7 <0.005
Clindamycin ≥8 ≥8 ≤0.25/≥8 72.9 ≥8 ≥8 ≤0.25/≥8 65.5 <0.005
Linezolid 2 2 ≤0.5/4 0 2 2 1/4 0 NA
Teicoplanin ≤0.5 ≤0.5 ≤0.5/2 0 ≤0.5 ≤0.5 ≤0.5/2 0 NA
Vancomycin ≤1 ≤1 ≤1/2 0 ≤0.5 1 ≤0.5/2 0 NA
Tetracycline ≤1 ≤1 ≤1/≥16 5.0 ≤1 ≤1 ≤1/≥16 9.0 <0.005
Fosfomycin ≤8 ≤8 ≤8/≥128 2.6 ≤8 ≤8 ≤8/≥128 1.3 <0.005
Fusidic acid ≤0.5 ≤0.5 ≤0.5/≥32 3.1 ≤0.5 ≤0.5 ≤0.5/≥32 2.6 0.3
Rifampicin ≤0.5 ≤0.5 ≤0.5/≥32 1.9 ≤0.5 ≤0.5 ≤0.5/≥32 1.4 0.5
Trimethoprim–
sulphamethoxazole
≤10 ≤10 ≤10/≥320 1.3 ≤10 ≤10 ≤10/≥320 3.3 <0.005
NA, not applicable.
aUnivariate analysis comparing non-susceptibility rates from the two sampling periods.
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All MRSA isolates were susceptible to vancomycin and
teicoplanin. The proportions of isolates showing teicoplanin
MICs of ≤0.5, 1 and 2 mg/L were 99.4%, 0.5% and 0.1% in
2004–2005, and 99.6%, 0.3% and 0.1% in 2010–2011, respec-
tively. MICs for vancomycin were not compared, as the
susceptibility tests from 2004–2005 did not differentiate
between ≤0.5 mg/L and 1 mg/L. However, we might have
underestimated the prevalence of a possible vancomycin MIC
creep, as elevated vancomycin MICs may be lost after
cryo-preservation and might not be evident with the use of
automated test systems [14].
Linezolid resistance was not detected; we found identical
MIC50 and MIC90 values in both sampling periods (2 mg/L).
In conclusion, the increased antimicrobial resistance to
tetracycline and trimethoprim–sulphamethoxazole is associ-
ated with the increasing proportion of LA-MRSA in
Germany.
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